<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34322852</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2240-2993</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Acta neurologica Belgica</Title><ISOAbbreviation>Acta Neurol Belg</ISOAbbreviation></Journal><ArticleTitle>Statins and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>979</StartPage><EndPage>986</EndPage><MedlinePgn>979-986</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13760-021-01753-8</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a paralytic, heterogeneous and progressive disease characterized by the degeneration of both upper and lower motor neurons. Several studies about the effects of statins drug on the risk of ALS showed contradictory results and evidence for this is inconclusive. So we aimed to perform a meta-analysis on previous studies to clarify the association between statin use and risk of ALS. The databases including PubMed, Scopus, and Web of science were searched in February 2021 for studies that reported the association between statin use and risk of ALS. The eligible studies had to provide a report on the effect of statin and the incidence of ALS while comparing it to the control group. Articles that had low statin exposure time, the absence of a control group and an unknown number of ALS patients were excluded. The rate ratio and 95% confidence interval (CI) were used for association measures in case-control and cohort studies. After full-text and abstract review, data from 8 studies with a total of 547,622 participants and 13,890 cases of ALS were entered in the present meta-analysis. We combined eight studies using a random-effect model and the RR for statin users among groups was 0.98 (95% CI 0.80-1.20) which indicates no association between statin and incidence of ALS. Also high heterogeneity was detected across the studies (Q value&#x2009;=&#x2009;26.62, P&#x2009;=&#x2009;.00; I<sup>2</sup>&#x2009;=&#x2009;72.71%). In our meta-analysis study, we found no association between statin use and an increase in ALS incidence. This result is in line with some previous studies and provides strong evidence that denies the possible association between statin uptake and disease induction.</AbstractText><CopyrightInformation>&#xa9; 2021. Belgian Neurological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nabizadeh</LastName><ForeName>Fardin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balabandian</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharafi</LastName><ForeName>Amir Mohammad</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Student's Scientific Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaderi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Student's Scientific Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostami</LastName><ForeName>Mohammad Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naser Moghadasi</LastName><ForeName>Abdorreza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8598-0911</Identifier><AffiliationInfo><Affiliation>Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. abdorrezamoghadasi@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Acta Neurol Belg</MedlineTA><NlmUniqueID>0247035</NlmUniqueID><ISSNLinking>0300-9009</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Statins</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34322852</ArticleId><ArticleId IdType="doi">10.1007/s13760-021-01753-8</ArticleId><ArticleId IdType="pii">10.1007/s13760-021-01753-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162&#x2013;172. https://doi.org/10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Prim 3:17071. https://doi.org/10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP (2018) Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc 93(11):1617&#x2013;1628. https://doi.org/10.1016/j.mayocp.2018.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bali T, Miller TM (2013) Management of amyotrophic lateral sclerosis. Mo Med 110(5):417&#x2013;421</Citation><ArticleIdList><ArticleId IdType="pubmed">24279194</ArticleId><ArticleId IdType="pmc">6179867</ArticleId></ArticleIdList></Reference><Reference><Citation>Faubion SS, Kapoor E, Moyer AM, Hodis HN, Miller VM (2019) Statin therapy: does sex matter? Menopause (New York) 26(12):1425&#x2013;1435. https://doi.org/10.1097/gme.0000000000001412</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/gme.0000000000001412</ArticleId></ArticleIdList></Reference><Reference><Citation>Enas EA, Kuruvila A, Khanna P, Pitchumoni CS, Mohan V (2013) Benefits &amp; risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians&#x2014;a population with the highest risk of premature coronary artery disease &amp; diabetes. Indian J Med Res 138(4):461&#x2013;491</Citation><ArticleIdList><ArticleId IdType="pubmed">24434254</ArticleId><ArticleId IdType="pmc">3868060</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;imi&#x107; I, Reiner &#x17d; (2015) Adverse effects of statins&#x2014;myths and reality. Curr Pharm Des 21(9):1220&#x2013;1226. https://doi.org/10.2174/1381612820666141013134447</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612820666141013134447</ArticleId><ArticleId IdType="pubmed">25312733</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaszewski M, St&#x119;pie&#x144; KM, Tomaszewska J, Czuczwar SJ (2011) Statin-induced myopathies. Pharmacol Rep 63(4):859&#x2013;866. https://doi.org/10.1016/s1734-1140(11)70601-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1734-1140(11)70601-6</ArticleId><ArticleId IdType="pubmed">22001973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23(7):871&#x2013;880. https://doi.org/10.1592/phco.23.7.871.32720</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.23.7.871.32720</ArticleId><ArticleId IdType="pubmed">12885101</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PD, Panza G, Zaleski A, Taylor B (2016) Statin-associated side effects. J Am Coll Cardiol 67(20):2395&#x2013;2410. https://doi.org/10.1016/j.jacc.2016.02.071</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.02.071</ArticleId><ArticleId IdType="pubmed">27199064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihl-Jensen G, Tsakiri A, Frederiksen JL (2015) Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 29(4):277&#x2013;291. https://doi.org/10.1007/s40263-015-0239-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-015-0239-x</ArticleId><ArticleId IdType="pubmed">25795002</ArticleId></ArticleIdList></Reference><Reference><Citation>Poly TN, Islam MM, Walther BA, Yang HC, Nguyen PA, Huang CW et al (2017) Exploring the association between statin use and the risk of Parkinson&#x2019;s disease: a meta-analysis of observational studies. Neuroepidemiology 49(3&#x2013;4):142&#x2013;151. https://doi.org/10.1159/000480401</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000480401</ArticleId><ArticleId IdType="pubmed">29145202</ArticleId></ArticleIdList></Reference><Reference><Citation>Poly TN, Islam MM, Walther BA, Yang HC, Wu CC, Lin MC et al (2020) Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology 54(3):214&#x2013;226. https://doi.org/10.1159/000503105</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503105</ArticleId><ArticleId IdType="pubmed">31574510</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM (2018) Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener 19(7&#x2013;8):538&#x2013;546. https://doi.org/10.1080/21678421.2018.1511731</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1511731</ArticleId><ArticleId IdType="pubmed">31112080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson L, Van Den Eeden, Tanner C, Albers K, McGuire V, et al (2009) Cholesterol-lowering drugs and risk of amyotrophic lateral sclerosis: a population-based case&#x2013;control study. Neuroepidemiology 33:77</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId><ArticleId IdType="pmc">2707599</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282(24):2340&#x2013;2346. https://doi.org/10.1001/jama.282.24.2340</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.282.24.2340</ArticleId><ArticleId IdType="pubmed">10612322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. Acta Cardiol Sin 32(6):631&#x2013;639. https://doi.org/10.6515/acs20160611a</Citation><ArticleIdList><ArticleId IdType="doi">10.6515/acs20160611a</ArticleId><ArticleId IdType="pubmed">27899849</ArticleId><ArticleId IdType="pmc">5126440</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuccori M, Montagnani S, Mantarro S, Capogrosso-Sansone A, Ruggiero E, Saporiti A et al (2014) Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs 28(3):249&#x2013;272. https://doi.org/10.1007/s40263-013-0135-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-013-0135-1</ArticleId><ArticleId IdType="pubmed">24435290</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE et al (2014) Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (Baltimore) 60(2):679&#x2013;686. https://doi.org/10.1002/hep.27157</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang CN, Okin PM (2014) Statin treatment, new-onset diabetes, and other adverse effects: a systematic review. Curr Cardiol Rep 16(3):461. https://doi.org/10.1007/s11886-013-0461-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-013-0461-4</ArticleId><ArticleId IdType="pubmed">24464306</ArticleId></ArticleIdList></Reference><Reference><Citation>Cederberg H, Stan&#x10d;&#xe1;kov&#xe1; A, Yaluri N, Modi S, Kuusisto J, Laakso M (2015) Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 58(5):1109&#x2013;1117. https://doi.org/10.1007/s00125-015-3528-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-015-3528-5</ArticleId><ArticleId IdType="pubmed">25754552</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70(13):1004&#x2013;1009. https://doi.org/10.1212/01.wnl.0000285080.70324.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshii Y, Hadano S, Otomo A, Kawabe K, Ikeda K, Iwasaki Y (2010) Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. https://doi.org/10.1212/WNL.0b013e3181e03bbe</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181e03bbe</ArticleId><ArticleId IdType="pubmed">20548050</ArticleId></ArticleIdList></Reference><Reference><Citation>Malfitano AM, Marasco G, Proto MC, Laezza C, Gazzerro P, Bifulco M (2014) Statins in neurological disorders: an overview and update. Pharmacol Res 88:74&#x2013;83. https://doi.org/10.1016/j.phrs.2014.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2014.06.007</ArticleId><ArticleId IdType="pubmed">24954580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R et al (2009) Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 73(20):1681&#x2013;1685. https://doi.org/10.1212/WNL.0b013e3181c1df1e</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB (2018) Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA&#x2019;s adverse event reporting system. Drug Saf 41(4):403&#x2013;413. https://doi.org/10.1007/s40264-017-0620-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0620-4</ArticleId><ArticleId IdType="pubmed">29427042</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen HT, Lash TL (2009) Statins and amyotrophic lateral sclerosis&#x2014;the level of evidence for an association. J Intern Med 266(6):520&#x2013;526. https://doi.org/10.1111/j.1365-2796.2009.02173.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2009.02173.x</ArticleId><ArticleId IdType="pubmed">19930099</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, Huisman MH, Roozekrans MH, de Jong SW et al (2014) Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 261(10):1949&#x2013;1956. https://doi.org/10.1007/s00415-014-7445-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7445-1</ArticleId><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H et al (2020) Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol 27(6):1010&#x2013;1016. https://doi.org/10.1111/ene.14190</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14190</ArticleId><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD (2020) Statin therapy and risk of Alzheimer&#x2019;s and age-related neurodegenerative diseases. Alzheimer&#x2019;s Dement (New York) 6(1):e12108. https://doi.org/10.1002/trc2.12108</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12108</ArticleId></ArticleIdList></Reference><Reference><Citation>Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J et al (2008) An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA&#x2019;s spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf 17(11):1068&#x2013;1076. https://doi.org/10.1002/pds.1643</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1643</ArticleId><ArticleId IdType="pubmed">18821724</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumacher J, Peter RS, Nagel G, Rothenbacher D, Rosenbohm A, Ludolph AC et al (2020) Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol 27(8):1405&#x2013;1414. https://doi.org/10.1111/ene.14300</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14300</ArticleId><ArticleId IdType="pubmed">32396653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Sheng L, Shang H (2013) Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 14(4):241&#x2013;245. https://doi.org/10.3109/21678421.2012.732078</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.732078</ArticleId><ArticleId IdType="pubmed">23134508</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltowski J (2010) Statins and ALS: the possible role of impaired LXR signaling. Med Sci Monit 16(3):RA73&#x2013;RA78</Citation><ArticleIdList><ArticleId IdType="pubmed">20190699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai L, Wang Y, Huo J, Li S, Wen Y, Liu Q et al (2021) Simvastatin accelerated motoneurons death in SOD1G93A mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles. Cell Death Dis 12(4):392. https://doi.org/10.1038/s41419-021-03669-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-03669-w</ArticleId><ArticleId IdType="pubmed">33846297</ArticleId><ArticleId IdType="pmc">8041862</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettinen TP, Bj&#xf6;rklund M (2015) Mevalonate pathway regulates cell size homeostasis and proteostasis through autophagy. Cell Rep 13(11):2610&#x2013;2620. https://doi.org/10.1016/j.celrep.2015.11.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.11.045</ArticleId><ArticleId IdType="pubmed">26686643</ArticleId><ArticleId IdType="pmc">4709259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffarian D, Wilson PW, Kannel WB (2008) Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease. Circulation 117(23):3031&#x2013;3038. https://doi.org/10.1161/circulationaha.107.738732</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.107.738732</ArticleId><ArticleId IdType="pubmed">18541753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar A (2020) The effects of statins on microglial cells to protect against neurodegenerative disorders: a mechanistic review. BioFactors (Oxford, England) 46(3):309&#x2013;325. https://doi.org/10.1002/biof.1597</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1597</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland AJ, Davey AK, Anoopkumar-Dukie S (2017) Statins reduce lipopolysaccharide-induced cytokine and inflammatory mediator release in an in vitro model of microglial-like cells. Mediat Inflamm. https://doi.org/10.1155/2017/2582745</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2582745</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi Saravi SS, Saeedi Saravi SS, Arefidoust A, Dehpour AR (2017) The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. Metab Brain Dis 32(4):949&#x2013;965. https://doi.org/10.1007/s11011-017-0021-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-017-0021-5</ArticleId><ArticleId IdType="pubmed">28578514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson&#x2019;s disease. J Neurosci 29(43):13543&#x2013;13556. https://doi.org/10.1523/jneurosci.4144-09.2009</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.4144-09.2009</ArticleId><ArticleId IdType="pubmed">19864567</ArticleId><ArticleId IdType="pmc">2862566</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL (2009) Statins: mechanisms of neuroprotection. Prog Neurobiol 88(1):64&#x2013;75. https://doi.org/10.1016/j.pneurobio.2009.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2009.02.002</ArticleId><ArticleId IdType="pubmed">19428962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sena A, Pedrosa R, Morais MG (2007) Beneficial effect of statins in multiple sclerosis: is it dose-dependent? Atherosclerosis 191(2):462. https://doi.org/10.1016/j.atherosclerosis.2006.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2006.08.010</ArticleId><ArticleId IdType="pubmed">17007861</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto K, Yoshii Y, Ikeda K (2009) Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice. Amyotroph Lateral Scler 10(5&#x2013;6):405&#x2013;409. https://doi.org/10.3109/17482960902870993</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902870993</ArticleId><ArticleId IdType="pubmed">19922131</ArticleId></ArticleIdList></Reference><Reference><Citation>Murinson BB, Haughey NJ, Maragakis NJ (2012) Selected statins produce rapid spinal motor neuron loss in vitro. BMC Musculoskelet Disord 13:100. https://doi.org/10.1186/1471-2474-13-100</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-13-100</ArticleId><ArticleId IdType="pubmed">22703530</ArticleId><ArticleId IdType="pmc">3487793</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Nandar W, Neely EB, Simmons Z, Connor JR (2016) Statins accelerate disease progression and shorten survival in SOD1(G93A) mice. Muscle Nerve 54(2):284&#x2013;291. https://doi.org/10.1002/mus.25048</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25048</ArticleId><ArticleId IdType="pubmed">26799243</ArticleId><ArticleId IdType="pmc">5848093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Highton-Williamson E, Caga J, Thornton N, Ramsey E, Zoing M, Kim WS, Halliday GM, Piguet O, Hodges JR, Farooqi IS, Kiernan MC (2018) Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimers Dis 61(2):773&#x2013;783. https://doi.org/10.3233/JAD-170660</Citation></Reference><Reference><Citation>Fern&#xc1;ndez-Eulate G, Ruiz-Sanz JI, Riancho J, Zufir&#xcd;a M, Gere&#xd1;u G, Fern&#xc1;ndez-Torr&#xd3;n R, Poza-Aldea JJ, Ondaro J, Espinal JB, Gonz&#xc1;lez-Chinch&#xd3;n G, Zulaica M, Ruiz-Larrea MB, L&#xd3;pez De Munain A, Gil-Bea FJ (2020) A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis. Amyotroph Later Scler Frontotemporal Degener 21(3&#x2013;4):252&#x2013;262. https://doi.org/10.1080/21678421.2020.1730904</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1730904</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen HT, Riis AH, Lash TL, Pedersen L&#xa0;(2010) Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes 3(4):413&#x2013;417. https://doi.org/10.1161/CIRCOUTCOMES.110.936278</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.110.936278</ArticleId><ArticleId IdType="pubmed">20530788</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>